You are here

SARC024

Active
A blanket protocol to study oral regorafenib in patients with refractory liposarcoma, osteogenic sarcoma, and Ewing/Ewing–like sarcomas
Type of Sarcoma: 
Refractory liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcomas
Drug: 
Regorafenib and placebo (for liposarcoma and osteogenic sarcoma only)
Accrual Status: 
Active
Overall Study Principal Investigator: 
Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

Richard F. Riedel, MD
Associate Professor of Medicine
Duke University School of Medicine

Christopher W. Ryan, MD
Medical Oncologist
Oregon Health and Science University

Steven Attia, DO
Medical Oncologist
Mayo Clinic
Co-Principal Investigators: 
Robert Maki, MD, PhD
Professor Pediatrics, Hematology & Oncology
Hofstra-Northwell School of Medicine

Richard F. Riedel, MD
Associate Professor of Medicine
Duke University School of Medicine

Christopher W. Ryan, MD
Medical Oncologist
Oregon Health and Science University

Steven Attia, DO
Medical Oncologist
Mayo Clinic

For more information about this trial and open sites: